Background: A disturbing trend in patient satisfaction research has been a willingness to accept low response rates as inevitable. However, it may not be appropriate to generalize data based on low responses to the full population of patients, since to do so may threaten the validity of the findings.
Method: Satisfaction data were collected from 19,556 inpatients discharged in 1994 from 76 hospitals using the 69-item NCG Patient Viewpoint Survey, an instrument that primarily uses a set of five response options, which are transformed to a 0- to 100-point scale. Surveys were sent to random samples of 100 to 1,400 patients, and were followed by postcard reminders. For each hospital sample, results for the "First 30%" were compared with those for "All Respondents," or the total number of respondents, for which the average response rate was 58%.
Findings: Results on individual scale scores and the subsequent improvement priorities for individual hospitals had a 50-50 chance of being different when the First 30% responses were compared with the All Respondents responses. For 9 out of 13 survey scales, the scores were significantly different between the First 30% and All Respondents when data were aggregated across all hospitals. For 42% of the 76 hospitals, a different set of scales would be identified as those most in need of improvement.
Discussion: The capriciousness of within-hospital differences based on the First 30% versus All Respondents brings into question the utility of patient satisfaction data based on low response rates even with a reliable instrument and with controlled, consistent data collection methods across hospitals. Target response rates should be set at 50% or higher. Additional research on the effects of response rates on patient satisfaction data are recommended.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s1070-3241(16)30245-0 | DOI Listing |
Background: Identifying strategies to engage with potential participants is critical for efficient enrollment in Alzheimer's Disease (AD) trials. Previous studies link faster speed of first contact with successful phone interview completion for Major Depressive Disorder (MDD) participants. This has not been examined in AD participants.
View Article and Find Full Text PDFBackground: Patients with Alzheimer's disease (AD) often experience burdensome neuropsychiatric symptoms, including agitation which occurs in both home and long-term care (LTC) facilities, and is associated with substantial increases in caregiver burden and LTC placements. AXS-05 (45-mg dextromethorphan/105-mg bupropion), a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist, approved by the FDA for major depressive disorder, is being investigated for treatment of AD agitation (ADA). AXS-05 has been evaluated in 2 randomized, double-blind studies: Phase 2 ADVANCE-1 (NCT03226522); Phase 3 ACCORD (NCT04797715).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Brigham and Women's Hospital and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
The most recent Alzheimer's clinical trials, including those which reported successful outcomes, use neuroimaging biomarkers of both amyloid and tau for screening participants and demonstrating a treatment effect on pathology. Some of these trials, notably Lecanemab, hint at a potential sex bias in treatment outcome, alluding to major implications for clinical practice when recommending treatment options. Sex differences in treatment response are not surprising given that women are at greater risk of progression to AD dementia, particularly if they carry APOEe4.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, UNSW Sydney, NSW, Australia.
Background: The effects of the COVID-19 pandemic extend beyond the viral impact and include social and psychological effects of the ensuing lockdowns and restrictions. Australia's lengthy lockdowns present an opportunity to study changes in the physical and mental wellbeing of older adults resulting from extended social isolation, a known risk factor for dementia, in the absence of high infection or mortality rates.
Method: Sydney Memory and Ageing Study, Sydney Centenarian Study, and CogSCAN study participants were mailed questionnaires about in-person and remote social contact and access to resources during the 2020 Sydney lockdown.
Alzheimers Dement
December 2024
Mayo Clinic, Jacksonville, FL, USA.
Background: Rapidly progressive dementia (RPD) is variably defined across published cohorts. A standardized definition is needed to support multicenter studies required to inform the causes of RPD and optimize recognition and management of treatment-responsive causes. An optimal definition will capture the broad spectrum of causes of RPD, adequately differentiate patients with rapid and typically progressive presentations of neurodegenerative disease, and be reliably implemented across healthcare settings and centers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!